UNIVERSITY OF FLORIDA

Researchers at the Medical University of South Carolina and the University of Florida developed a novel strategy to treat type 1 diabetes using tagged beta cell transplants and localized immune protection via Tregs. This approach aims to create an off-the-shelf solution, overcoming organ shortages and immune rejection challenges. The study, published in Cell Reports, demonstrated the viability of the method in mice, showing protected beta cells remained functional. Future research will focus on human applications and expanding the approach to other diseases.

New research suggests yoga can help ease emotional stress and depression in women with gynecological, gastrointestinal, or thoracic cancer. A 10-week program combining yoga, mindfulness, and psychotherapy showed reduced anxiety and depression symptoms, particularly beneficial for women of color. Published in 'Integrative Cancer Therapies'.

AmiLyfe Bioscience's innovative amino acid hydration technology aims to improve global health by enhancing water absorption, with potential applications in treating dehydration, malnutrition, and gut health issues, particularly in vulnerable populations.

The Eric Sorensen Motor Speech Program (ESMSP) was developed in partnership with UCF, JU, and UF to improve services for adults with motor speech disorders. Inspired by patient Eric Sorensen's recovery from a traumatic brain injury, the program was funded by his parents. ESMSP aims to grow into a specialized clinic, starting with virtual and in-person support groups led by Jackie Hurst, who also manages the program. The initiative includes two phases: Phase I focuses on SIMS-trained SLPs providing treatment, and Phase II will study acquired motor speech disorders through intensive services.

Prenetics, in partnership with David Beckham, launches IM8, a health and wellness brand with two premium products: Daily Ultimate Essentials and Daily Ultimate Longevity, available at IM8health.com, shipping to 31 countries. IM8 products are clinically proven, third-party tested, and designed to support daily health and long-term vitality.

UF's Precision Medicine Program integrates pharmacogenetic data into Epic’s Genomic Module via HL7 standards, introducing genomic indicators in EHR to enhance clinical decision support and personalized medicine.

Genascence's GNSC-001, a gene therapy for OA, received FDA Fast Track designation. GNSC-001 targets IL-1, a key mediator in OA pathogenesis, aiming for long-term inhibition with a single injection. Phase 1 data showed GNSC-001 was well-tolerated and improved pain and function scores.